文献速递心境障碍

Omega-3多不饱和脂肪酸通过LOX和CYP450脂质介质抗炎:与重性抑郁及人类海马神经发生相关

Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis.
PubMed 文献 · Mol Psychiatry · 2021-06-16

该研究结合体外人类海马祖细胞实验与22例重性抑郁障碍患者随机对照试验,发现EPA和DHA通过LOX及CYP450代谢产物(5-HEPE、4-HDHA、18-HEPE、20-HDHA、17(18)-EpETE、19(20)-EpDPA)防止细胞因子诱导的神经发生减少和凋亡增加,且患者血浆中这些代谢物随EPA或DHA治疗升高,部分与抑郁症状较轻相关。

要点

  • EPA和DHA经LOX与CYP450途径生成的脂质介质可保护人类海马神经发生并抗凋亡。
  • sEH抑制剂TPPU与17(18)-EpETE或19(20)-EpDPA共处理进一步增强神经发生和抗凋亡效应。
  • 抑郁患者补充EPA或DHA后血浆中相同LOX/CYP450代谢物升高,且较高水平与抑郁症状较轻相关。

核心结论

  • LOX和CYP450来源的EPA/DHA生物活性脂质介质是人类海马神经发生和抑郁的神经保护分子靶点。
  • sEH抑制剂可能是治疗抑郁症状的潜在策略。

研究设计与样本

  • 体外研究使用人类海马祖细胞系HPC0A07/03C,先用EPA或DHA预处理,再暴露于IL1β、IL6和IFN-α。
  • 临床研究纳入22例DSM-IV重性抑郁障碍患者,随机分配接受EPA 3.0 g/天或DHA 1.4 g/天治疗12周。

主要发现

  • EPA和DHA prevented cytokines-induced reduction in neurogenesis and increase in apoptosis in vitro。
  • 首次用质谱脂质组学在人类海马神经元上清中检测到5-HEPE、4-HDHA、18-HEPE、20-HDHA、17(18)-EpETE和19(20)-EpDPA。
  • 这些代谢物共处理可防止细胞因子诱导的神经发生减少和凋亡增加。
  • 17(18)-EpETE、19(20)-EpDPA与sEH抑制剂TPPU共处理进一步增强神经发生和抗凋亡效应。
  • 患者接受EPA或DHA治疗后血浆中相同LOX和CYP450脂质代谢物升高,且较高水平与抑郁症状较轻相关。

关键数值与推荐

  • 临床治疗剂量为EPA 3.0 g/天或DHA 1.4 g/天,疗程12周。
  • 体外使用IL1β、IL6和IFN-α诱导细胞因子损伤模型。

临床怎么用

  • EPA和DHA的抗炎、神经保护和抗抑郁效应可能部分通过LOX和CYP450脂质代谢物介导。
  • sEH抑制剂联合EPA/DHA代谢物可能增强神经保护作用,但需进一步临床验证。
  • 血浆LOX/CYP450代谢物水平或可作为抑郁患者对Omega-3治疗反应的潜在生物标志物。

局限性

  • 临床样本量较小(n=22),结果需更大样本验证。
  • 体外实验使用永生化海马祖细胞系,与人体生理状态存在差异。
  • 代谢物与抑郁症状严重程度的相关性仅为初步证据,未明确因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can exert antidepressant, anti-inflammatory and neuroprotective properties, but the exact molecular mechanism underlying their effects is still not fully understood. We conducted both in vitro and clinical investigations to test which EPA or DHA metabolites are involved in these anti-inflammatory, neuroprotective and antidepressant effects. In vitro, we used the human hippocampal progenitor cell line HPC0A07/03C, and pre-treated cells with either EPA or DHA, followed by interleukin 1beta (IL1β), IL6 and interferon-alpha (IFN-α). Both EPA and DHA prevented the reduction in neurogenesis and the increase in apoptosis induced by these cytokines; moreover, these effects were mediated by the lipoxygenase (LOX) and cytochrome P450 (CYP450) EPA/DHA metabolites, 5-hydroxyeicosapentaenoic acid (HEPE), 4-hydroxydocosahexaenoic acid (HDHA), 18-HEPE, 20-HDHA, 17(18)-epoxyeicosatetraenoic acid (EpETE) and 19(20)-epoxydocosapentaenoic acid (EpDPA), detected here for the first time in human hippocampal neurones using mass spectrometry lipidomics of the supernatant. In fact, like EPA/DHA, co-treatment with these metabolites prevented cytokines-induced reduction in neurogenesis and apoptosis. Moreover, co-treatment with 17(18)-EpETE and 19(20)-EpDPA and the soluble epoxide hydroxylase (sEH) inhibitor, TPPU (which prevents their conversion into dihydroxyeicosatetraenoic acid (DiHETE)/ dihydroxydocosapentaenoic acid (DiHDPA) metabolites) further enhanced their neurogenic and anti-apoptotic effects. Interestingly, these findings were replicated in a sample of n = 22 patients with a DSM-IV Major Depressive Disorder, randomly assigned to treatment with either EPA (3.0 g/day) or DHA (1.4 g/day) for 12 weeks, with exactly the same LOX and CYP450 lipid metabolites increased in the plasma of these patients following treatment with their precursor, EPA or DHA, and some evidence that higher levels of these metabolites were correlated with less severe depressive symptoms. Overall, our study provides the first evidence for the relevance of LOX- and CYP450-derived EPA/DHA bioactive lipid metabolites as neuroprotective molecular targets for human hippocampal neurogenesis and depression, and highlights the importance of sEH inhibitors as potential therapeutic strategy for patients suffering from depressive symptoms.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Borsini A, Nicolaou A, Camacho-Muñoz D, et al. Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis. Mol Psychiatry. 2021. PMID: 34131267. doi:10.1038/s41380-021-01160-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。